Lilly’s New Anti-Amyloid Play Hinges On Tau Bet
Redesigned Phase III Trial May Confirm Phase II Donanemab Results
TRAILBLAZER-ALZ met the primary, but not most secondary endpoints. Lilly said efficacy of its amyloid-clearing agent depends on tau levels at baseline and reductions in some parts of the brain.
You may also be interested in...
Company maintains that the upcoming Medicare national coverage policy for Alzheimer’s drugs should not impose the same access restrictions on drugs with better evidence of effectiveness than others.
The upcoming filing of Lilly's Alzheimer's antibody donanemab dominated the company's second quarter call. Lilly is also developing a new blood test to confirm diagnosis and a second-generation antibody.
Lilly expects results from donanemab ongoing confirmatory trial in 2023, while Biogen has nine years to finish its postmarket study. CEO David Ricks discusses impact of aducanumab approval backlash, pricing and national coverage decision at STAT summit.